Comment on: Selvin et al. sRAGE and Risk of Diabetes, Cardiovascular Disease, and Death. Diabetes 2013;62:2116–2121

  1. Coen D.A. Stehouwer
  1. Department of Internal Medicine, Division of General Internal Medicine, University Hospital Maastricht, Maastricht, the Netherlands.
  1. Corresponding author: Casper G. Schalkwijk, c.schalkwijk{at}intmed.unimaas.nl, c.schalkwijk{at}maastrichtuniversity.nl.

Selvin et al. (1) report that, in a community-based population, lower levels of soluble circulating receptor for advanced glycation end products (sRAGEs) at baseline were independently associated with risk of diabetes, coronary heart disease, and all-cause mortality during 18 years of follow-up. These findings are challenging since we and others have previously reported that higher levels of sRAGE are associated with incident cardiovascular disease and all-cause mortality in type 1 (2,3) and 2 diabetes (4,5).

The reasons for these contradictory findings are not clear. As …

| Table of Contents
OPEN ACCESS ARTICLE